| Literature DB >> 34070150 |
Yumeng Zhang1, Guohui Shi1, Zhonghua Luo1, Jiewen Wang1, Shao Wu1, Xiaoshu Zhang1,2, Yuqing Zhao1,2.
Abstract
Hepatic fibrosis would develop into cirrhosis or cancer without treating. Hence, it is necessary to study the mechanism and prevention methods for hepatic fibrosis. Gynostemma pentaphyllum is a traditional medicinal material with a high medicinal and health value. In this study, nineteen compounds obtained from G. pentaphyllum were qualitative and quantitative by HPLC-FT-ICR MS and HPLC-UV, respectively. Among them, the total content of 19 gypenosides accurately quantified reaches 72.21 mg/g and their anti-proliferation against t-HSC/Cl-6 cells indicated compound 19 performed better activity (IC50: 28.1 ± 2.0 μM) than the other compounds. Further network pharmacology study demonstrated that compound 19 mainly plays an anti-fibrosis role by regulating the EGFR signaling pathway, and the PI3K-Akt signaling pathway. Overall, the verification result indicated that compound 19 appeared to be nontoxic to LO2, was able to modulate the PI3K/Akt signal, led to subG1 cells cycle arrest and the activation of mitochondrial-mediated apoptosis of t-HSC/Cl-6 cells for anti-hepatic fibrosis.Entities:
Keywords: G. pentaphyllum; PI3K/Akt signaling pathway; hepatic fibrosis; network pharmacology
Year: 2021 PMID: 34070150 PMCID: PMC8158484 DOI: 10.3390/molecules26103006
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1The structures of compounds 1–19.
The peak information of HPLC-FT-ICR MS analysis.
| No. | Retention Time | [M−H]+ | Error | Compounds |
|---|---|---|---|---|
| 1 | 8.37 | 1075.57105 | −1.49 |
|
| 2 | 9.19 | 1077.58650 | −1.30 |
|
| 3 | 9.90 | 1047.57184 | 2.57 |
|
| 4 | 10.09 | 1047.56959 | 4.72 |
|
| 5 | 10.19 | 1045.55885 | 0.03 |
|
| 6 | 15.21 | 1061.59252 | −2.20 |
|
| 7 | 15.30 | 1061.59273 | −2.39 |
|
| 8 | 23.39 | 1103.60267 | −1.74 |
|
| 9 | 26.67 | 883.50701 | −1.08 |
|
| 10 | 28.49 | 913.51883 | −2.42 |
|
| 11 | 30.38 | 751.46499 | −1.59 |
|
| 12 | 31.38 | 899.53926 | −2.11 |
|
| 13 | 31.76 | 911.50313 | −2.36 |
|
| 14 | 32.51 | 911.50094 | 0.04 |
|
| 15 | 33.13 | 955.52763 | −0.46 |
|
| 16 | 36.41 | 953.51526 | −3.87 |
|
| 17 | 36.92 | 953.51415 | −2.73 |
|
| 18 | 43.40 | 953.55206 | −4.33 |
|
| 19 | 47.01 | 969.58297 | −3.87 |
|
Figure 2The HPLC-FT-ICR MS chromatogram of G. pentaphyllum.
The methodology investigation results of simultaneous determination of 19 gypenosides.
| Compounds | Linear Regression Data | Precision RSD (%) | Stability RSD (%) | |||
|---|---|---|---|---|---|---|
| Linearity Curve | R2 | Linear Range (mg/mL) | Intra-Day | Inter-Day | ||
|
| Y = 4 × 106x + 2.764 × 104 | 0.9992 | 0.01–1 | 1.86 | 1.38 | 2.47 |
|
| Y = 1 × 106x + 8.823 × 103 | 0.9994 | 0.01–1 | 2.08 | 2.57 | 2.20 |
|
| Y = 5 × 106x + 1.406 × 104 | 0.9993 | 0.01–1 | 1.57 | 2.02 | 1.93 |
|
| Y = 5 × 106x + 2.068 × 104 | 0.9991 | 0.01–1 | 1.62 | 1.54 | 1.52 |
|
| Y = 1 × 106x + 8.790 × 103 | 0.9994 | 0.01–1 | 1.05 | 1.99 | 1.76 |
|
| Y = 3 × 106x + 1.062 × 104 | 0.9991 | 0.01–1 | 1.13 | 1.07 | 1.35 |
|
| Y = 4 × 106x + 1.333 × 104 | 0.9991 | 0.01–1 | 1.25 | 0.98 | 1.88 |
|
| Y = 4 × 106x + 2.874 × 103 | 0.9991 | 0.01–1 | 1.37 | 2.88 | 1.06 |
|
| Y = 6 × 106x + 1.479 × 104 | 0.9989 | 0.01–1 | 1.67 | 1.49 | 2.50 |
|
| Y = 5 × 106x − 7.298 × 103 | 0.9992 | 0.01–1 | 1.27 | 2.38 | 2.04 |
|
| Y = 7 × 106x + 4.892 × 104 | 0.9992 | 0.01–1 | 1.94 | 1.94 | 1.69 |
|
| Y = 5 × 106x + 4.022 × 104 | 0.9992 | 0.01–1 | 2.11 | 1.74 | 2.51 |
|
| Y = 3 × 106x + 2.574 × 104 | 0.9991 | 0.01–1 | 2.04 | 2.03 | 2.15 |
|
| Y = 8 × 106x − 1.312 × 104 | 0.9991 | 0.01–1 | 2.68 | 2.22 | 2.81 |
|
| Y = 3 × 106x − 2.803 × 104 | 0.9991 | 0.01–1 | 2.53 | 1.25 | 1.44 |
|
| Y = 6 × 106x + 4.048 × 104 | 0.9992 | 0.01–1 | 1.68 | 2.79 | 2.85 |
|
| Y = 2 × 106x − 1.297 × 103 | 0.9992 | 0.01–1 | 1.79 | 1.30 | 2.66 |
|
| Y = 4 × 106x + 2.101 × 104 | 0.9990 | 0.01–1 | 2.05 | 2.74 | 1.57 |
|
| Y = 6 × 106x + 5.441 × 104 | 0.9992 | 0.01–1 | 1.98 | 1.83 | 1.09 |
Figure 3The content of compounds in G. pentaphyllum extracts.
Inhibitory activity (IC50, μM, 36 h) of compounds in G. pentaphyllum extracts in activated t-HSC/Cl-6 cells and LO2 cells.
| Compounds | t-HSC/Cl-6 | LO2 | Compounds | t-HSC/Cl-6 | LO2 |
|---|---|---|---|---|---|
|
| >200 | >200 |
| 43.6 ± 2.7 *** | >200 |
|
| 50.4 ± 1.4 *** | >200 |
| >200 | >200 |
|
| >200 | >200 |
| 105.6 ± 2.6 * | >200 |
|
| 126.4 ± 9.7 * | >200 |
| >200 | >200 |
|
| >200 | >200 |
| >200 | >200 |
|
| 99.9 ± 4.5 * | >200 |
| 44.7 ± 1.0 *** | >200 |
|
| 152.0 ± 7.4 | >200 |
| 66.1 ± 3.8 *** | >200 |
|
| 68.8 ± 3.2 *** | >200 |
| 58.0 ± 2.9 *** | >200 |
|
| 113.6 ± 7.8 * | >200 |
| 28.1 ± 2.0 *** | >200 |
|
| >200 | >200 |
| 185.3 ± 10.1 | >200 |
The results were shown as the mean value ± SD. * p < 0.05, *** p < 0.001, when compared to LO2 values by Student’s t-test, Silymarin was used as positive control.
Figure 4Drug–disease interaction network analysis. (a) The Venn diagram of targets; (b) the PPI network analysis of gypenosides and liver fibrosis. In a, the overlapping genes were selected as key targets for further analysis.
Figure 5Histogram of the KEGG pathway of gypenosides.
Figure 6GO analysis bubble chart of gypenosides. MF: molecular function; BP: biological process; CC: cellular component.
Figure 7Interactive network of “gypenosides–target–pathway–liver fibrosis”.
Figure 8(a) The cell cycle analysis by flow cytometry of compound 19. *** p < 0.001; (b) morphological changes and the nuclear morphological changes of t-HSC/Cl-6 cells and LO2 cells treated with compound 19 for 36 h. Control cells were incubated with DMSO. The arrow indicates apoptotic cells.
Figure 9(a) The mechanism of compound 19 inducing apoptosis and arresting t-HSC/Cl-6 cells cycle; (b) effects of compound 19 on the ratio of protein in t-HSC/Cl-6 cells. Data are presented as the means ± SD of three independent experiments. ** p < 0.01, *** p < 0.001 compared with β-actin.
Figure 10Possible anti-mechanisms of compound 19 in t-HSC/Cl-6 cells.